Table 3.
US findings at baseline
| No | Percentage | |
|---|---|---|
| Joint erosions (any site) | 16/131 | 10% |
| SA-SD bursitis | 98/165 (70 bilateral) | 59.39% |
| GH JE/SH | 93/161 (68 bilateral) | 57.76% (42.23% bilateral) |
| LHBT tenosynovitis | 125/161 (90 bilateral) | 77.63% (55.9%) |
| PD-shoulder (any site) | 49/149 (9 bilateral) | 32.88% (6.04%) |
| Wrist JE/SH | 39/145 (25 bilateral) | 26.98% (17.24%) |
| PD-wrist (radio-carpal) | 39/150 (25 bilateral) | 26% (16.66% bilateral) |
| MCP JE/SH | 20/138 (12 bilateral) | 14.49% (8.69% bilateral) |
| Hip bursitis (any site) | 36/136 (22 bilateral) | 26.47% (16.17%) |
| Knee JE/SH | 27/136 (10 bilateral) | 19.85% (7.35% bilateral) |
| Calcifications suggestive for CPPD | 31/140 | 21.98% |
| Enthesitis (heel, knee) | 10/140 (4 bilateral) | 7.14% (2.85% bilateral) |
| IMT AxA > 1 mm | 12/132 | 9.09% |
| Pathological TA | 10/132 | 7.57% |
Abbreviations: AxA axillary arteries, GH gleno-humeral, IMT intima-media thickness, JE joint effusion, LHBT long head biceps tendón, MCF metacarpophalangeal, PD Power Doppler, SA-SD subacromion-subdeltoideal, SH synovial hypertrophy, TA temporal arteries